Circulating Interleukin-22 Is a Biomarker for Newly Diagnosed Type 2 Diabetes Mellitus and Associated with Hypoglycemic Effect of Sitagliptin.

IF 2.8 3区医学 Q3 ENDOCRINOLOGY & METABOLISM Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Pub Date : 2025-03-03 eCollection Date: 2025-01-01 DOI:10.2147/DMSO.S509866

Peiye Sun, Yuxi Xiao, Yuan Dong, Yixiang Feng, Hongting Zheng, Xiaoyu Liao

{"title":"Circulating Interleukin-22 Is a Biomarker for Newly Diagnosed Type 2 Diabetes Mellitus and Associated with Hypoglycemic Effect of Sitagliptin.","authors":"Peiye Sun, Yuxi Xiao, Yuan Dong, Yixiang Feng, Hongting Zheng, Xiaoyu Liao","doi":"10.2147/DMSO.S509866","DOIUrl":null,"url":null,"abstract":"Purpose: Interleukin-22 (IL-22) has been demonstrated to be involved in the regulation of glucose metabolism, insulin resistance and inflammation response, which indicates that IL-22 might be associated with the occurrence and progression of diabetes. This study aimed to assess serum IL-22 levels in participants with type 2 diabetes mellitus (T2DM) and analyze the association between IL-22 levels and T2DM risk.Methods: Serum IL-22 concentrations of recruited healthy participants (n=48), newly diagnosed T2DM participants (n=46), and T2DM participants receiving placebo (n=7) or dipeptidyl peptidase-4 inhibitors (DPP-4i) sitagliptin monotherapy (n=7) were measured using a commercial enzyme-linked immunosorbent assay (ELISA) kit. Mice fed a high-fat diet (HFD) were administered sitagliptin and evaluated for IL-22 and intestinal inflammation-related indicators.Results: Serum IL-22 levels were higher in the T2DM group (127.16 ± 75.35) than in healthy controls (69.18 ± 32.83, p < 0.001), significantly negatively correlated with high-density lipoprotein cholesterol (HDL-C), and positively correlated with body mass index (BMI), glycosylated hemoglobin (HbA1c) and fasting plasma glucose (FPG), regardless of adjustment for sex and age. Multivariate logistic regression analysis showed that serum IL-22 levels were associated with the risk of T2DM (OR = 2.37, 95% CI = 1.27-4.42, p = 0.007). Additionally, sitagliptin treatment decreased the levels of IL-22 in the serum and colon tissues of T2DM participants and HFD mice. Moreover, intestinal inflammation was improved, and retinoid acid-related orphan receptor γt (RORγt, a marker of Th17 cells)- positive cells in the colon of HFD mice were decreased after sitagliptin treatment, which might be related to the reduction of IL-22.Conclusion: Serum IL-22 is a significant independent risk factor for T2DM, implying that circulating IL-22 may be a predictive biomarker and therapeutic target for T2DM.","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"703-713"},"PeriodicalIF":2.8000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11887505/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DMSO.S509866","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Interleukin-22 (IL-22) has been demonstrated to be involved in the regulation of glucose metabolism, insulin resistance and inflammation response, which indicates that IL-22 might be associated with the occurrence and progression of diabetes. This study aimed to assess serum IL-22 levels in participants with type 2 diabetes mellitus (T2DM) and analyze the association between IL-22 levels and T2DM risk.

Methods: Serum IL-22 concentrations of recruited healthy participants (n=48), newly diagnosed T2DM participants (n=46), and T2DM participants receiving placebo (n=7) or dipeptidyl peptidase-4 inhibitors (DPP-4i) sitagliptin monotherapy (n=7) were measured using a commercial enzyme-linked immunosorbent assay (ELISA) kit. Mice fed a high-fat diet (HFD) were administered sitagliptin and evaluated for IL-22 and intestinal inflammation-related indicators.

Results: Serum IL-22 levels were higher in the T2DM group (127.16 ± 75.35) than in healthy controls (69.18 ± 32.83, p < 0.001), significantly negatively correlated with high-density lipoprotein cholesterol (HDL-C), and positively correlated with body mass index (BMI), glycosylated hemoglobin (HbA1c) and fasting plasma glucose (FPG), regardless of adjustment for sex and age. Multivariate logistic regression analysis showed that serum IL-22 levels were associated with the risk of T2DM (OR = 2.37, 95% CI = 1.27-4.42, p = 0.007). Additionally, sitagliptin treatment decreased the levels of IL-22 in the serum and colon tissues of T2DM participants and HFD mice. Moreover, intestinal inflammation was improved, and retinoid acid-related orphan receptor γt (RORγt, a marker of Th17 cells)- positive cells in the colon of HFD mice were decreased after sitagliptin treatment, which might be related to the reduction of IL-22.

Conclusion: Serum IL-22 is a significant independent risk factor for T2DM, implying that circulating IL-22 may be a predictive biomarker and therapeutic target for T2DM.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

5.90

自引率

6.10%

发文量

431

审稿时长

16 weeks

期刊介绍： An international, peer-reviewed, open access, online journal. The journal is committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication.